share_log

Virpax Pharmaceuticals | DEFA14A: Others

Virpax Pharmaceuticals | DEFA14A: Others

Virpax製藥 | DEFA14A:其他
美股SEC公告 ·  07/08 16:38

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into...Show More
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into three classes, with the current composition being seven directors. The company has also updated its proxy card to reflect the nominee changes and advises stockholders who have already voted and do not wish to change their vote that no further action is required. The proxy materials, including the amended notice, proxy statement, supplement, updated proxy card, and the 2023 Annual Report, are available at www.proxyvote.com.
Virpax藥品公司已經發行了一份補充文件至其明確的代理聲明中,詳情列明其於2024年7月29日舉行的股東年會之前的重大變更。該補充文件於2024年7月5日公佈,隨着公司與機構投資者達成250萬美元融資協議,使其董事會重組,5名董事辭職,新任命4名,包括Judy Su,Jatinder Dhaliwal,Katharyn Field和Gary Herman。Jeffrey Gudin博士的辭職導致Gary Herman接任他的職位,並在即將到來的年會上競選連任。董事會被重組爲三個階層,目前成員爲七名董事。公司還更新了其代理卡以反映候選人的更改,並建議已經投票並且不希望更改投票意向的股東無需採取任何進一步的行動。代理材料,包括修訂的通知、代理聲明、補充文件、更新的代理卡和2023年度報告,可在www.proxyvote.com上獲得。
Virpax藥品公司已經發行了一份補充文件至其明確的代理聲明中,詳情列明其於2024年7月29日舉行的股東年會之前的重大變更。該補充文件於2024年7月5日公佈,隨着公司與機構投資者達成250萬美元融資協議,使其董事會重組,5名董事辭職,新任命4名,包括Judy Su,Jatinder Dhaliwal,Katharyn Field和Gary Herman。Jeffrey Gudin博士的辭職導致Gary Herman接任他的職位,並在即將到來的年會上競選連任。董事會被重組爲三個階層,目前成員爲七名董事。公司還更新了其代理卡以反映候選人的更改,並建議已經投票並且不希望更改投票意向的股東無需採取任何進一步的行動。代理材料,包括修訂的通知、代理聲明、補充文件、更新的代理卡和2023年度報告,可在www.proxyvote.com上獲得。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息